Glucocorticoids and Pulmonary Hypertension
Prospective Study of Glucocorticoids as a Mechanism to Treat Pulmonary Hypertension
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Manish Aggarwal, MD
- Phone Number: 314-273-8329
- Email: maggarwal@wustl.edu
Study Contact Backup
- Name: Ronald M Grady, MD
- Phone Number: 314-454-6095
- Email: rmgrady@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- St. Louis Children's Hospital
-
Contact:
- Manish Aggarwal, MD
- Phone Number: 314-454-6095
- Email: maggarwal@wustl.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- premature, BPD, >36 wga
- pulmonary hypertension evidence by echocardiogram
Exclusion Criteria:
- poor ventilation/oxygenation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Echo estimation of RV pressure
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994 Feb;144(2):275-85.
- Perros F, Dorfmuller P, Montani D, Hammad H, Waelput W, Girerd B, Raymond N, Mercier O, Mussot S, Cohen-Kaminsky S, Humbert M, Lambrecht BN. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Feb 1;185(3):311-21. doi: 10.1164/rccm.201105-0927OC. Epub 2011 Nov 22.
- Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Nov 1;186(9):897-908. doi: 10.1164/rccm.201202-0335OC. Epub 2012 Sep 6.
- Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32. doi: 10.1152/ajplung.00217.2009. Epub 2009 Sep 11.
- Langleben D, Reid LM. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy. Lab Invest. 1985 Mar;52(3):298-303.
- Wang W, Wang YL, Chen XY, Li YT, Hao W, Jin YP, Han B. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep. 2011 Jun;38(5):3277-84. doi: 10.1007/s11033-010-0390-x. Epub 2011 Mar 23.
- Ogawa A, Nakamura K, Mizoguchi H, Fujii N, Fujio H, Kusano KF, Ohe T, Ito H. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011 Jan 1;183(1):139-40. doi: 10.1164/ajrccm.183.1.139. No abstract available.
- Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, Miyazaki I, Asanuma M, Miyaji K, Miura D, Kusano KF, Date H, Ohe T. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation. 2005 Sep 20;112(12):1806-12. doi: 10.1161/CIRCULATIONAHA.105.536169. Epub 2005 Sep 12. Erratum In: Circulation. 2006 Apr 18;113(15):e713.
- Aggarwal M, Grady RM. Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication. Cardiol Young. 2017 Sep;27(7):1410-1412. doi: 10.1017/S1047951117000464. Epub 2017 May 16.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Infant, Newborn, Diseases
- Signs and Symptoms, Respiratory
- Lung Injury
- Infant, Premature, Diseases
- Ventilator-Induced Lung Injury
- Hypertension
- Lung Diseases
- Hypertension, Pulmonary
- Hypoxia
- Bronchopulmonary Dysplasia
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Glucocorticoids
Other Study ID Numbers
Other Study ID Numbers
- LD2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07612657Not yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
NCT07217522RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
-
NCT07604805RecruitingIdiopathic Pulmonary Hypertension
-
NCT07266519Not yet recruiting
-
NCT07172334Not yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
NCT02565030CompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension
-
NCT03205085UnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
-
NCT00882947Completed
-
NCT07318597RecruitingPulmonary Arterial Hypertension (PAH)
Clinical Trials on GlucoCorticoid
-
NCT07151456Not yet recruitingIdiopathic Nephrotic Syndrome
-
NCT07159893Not yet recruitingDemyelinating Autoimmune Diseases, CNS | Autoimmune Diseases | Neuromyelitis Optica
-
NCT01051999CompletedCystic Fibrosis | Immune Function
-
NCT03111979Suspended
-
NCT03566524CompletedKetosis Prone Diabetes
-
NCT06234852CompletedSystemic Lupus Erythematosus, SLE
-
NCT03999684CompletedAdenoid Cystic Carcinoma
-
NCT01668615CompletedImmune Thrombocytopenic Purpura
-
NCT03466801TerminatedIdiopathic Membranous Nephropathy
-
NCT06395883RecruitingOsteoporosis | Inflammatory Rheumatism | Osteoporosis, Steroid Induced